Research Article
[Retracted] Additional Benefits Conferred by Endoscopic Sclerotherapy to Liver Cirrhosis Patients Receiving Endoscopic Variceal Ligation
Table 6
The long-term rebleeding rate, recurrence rate, and mortality among three groups after treatment.
| | Group | Long-term rebleeding (n (%)) | Recurrence rate (n (%)) | Mortality (n (%)) |
| | Ligation group (n = 45) | 18 (40.00) | 13 (28.89) | 8 (17.78) | | Sclerotherapy group (n = 45) | 19 (42.22) | 14 (31.11) | 7 (15.56) | | Combined group (n = 45) | 6 (13.33) | 5 (11.11) | 1 (2.22) | | χ2/P (ligation vs. sclerotherapy) | 0.046/0.830 | 0.053/0.818 | 0.080/0.777 | | χ2/P (ligation vs. combined) | 8.182/0.004 | 4.444/0.035 | 6.049/0.014 | | χ2/P (sclerotherapy vs. combined) | 9.360/0.002 | 5.404/0.020 | 4.939/0.026 |
|
|
